Skip to main content

Table 1 Baseline disease characteristics

From: Serum cytokine profiles predict survival benefits in patients with advanced hepatocellular carcinoma treated with sorafenib: a retrospective cohort study

  Cohort 1: HAIC(n = 104) Cohort 2: Sorafenib(n = 39) P-valuea
Age (y), median, range 65.0 (40–82) 67.0 (37–83) 0.306
Gender(Male: Female) 86:18 32:7 0.928
Child-Pugh score 6.5 5.9 0.028
 Child-Pugh A 60 31 0.042
 Child-Pugh B 40 8
 Child-Pugh C 4 0
Performance status (0/1/2) 91/11/2 37/1/1 0.301
Prior treatment (surgical resection) 5.2% (20) 33.3% (13) 0.075
Prior treatment (radiofrequency ablation) 51.0% (53) 53.8% (21) 0.759
Prior treatment (TACE/TAE) 51.9% (54) 76.9% (30) 0.007
Size of dominant tumour (mm) 32.3 ± 21.2 42.0 ± 27.9 0.066
Multiple tumour 69.2% (72) 71.8% (28) 0.766
AFP (ng/ml) mean ± SE 13,110.5 ± 5278.7 3438.7 ± 1123.3 0.259
AFP-L3 (%) ± SE 28.6 ± 2.7 38.8 ± 5.4 0.073
DCP (mAU/ml) ± SE 21,194.0 ± 6814.7 5418.4 ± 2896.5 0.161
Vascular invasion (%) 35.6% (37) 17.9% (7) 0.042
Distant metastasis (%) 10.6% (11) 35.9% (14) <0.001
BCLC stage (B/C/D) 47/51/6 18/21/0 0.303
Tumor responses by mRECIST (CR / PR) 34.6% (36) 2.6% (1) <0.001
  1. AFP alpha-fetoprotein, AFP-L3 lectin-reactive AFP, BCLC Barcelona-Clínic Liver Cancer, CR complete response, DCP des-gamma carboxyprothrombin, HAIC hepatic arterial infusion chemotherapy, PR partial response, SD standard deviation, SE standard error, TACE/TAE transcatheter arterial chemoembolization/transcatheter arterial embolization)
  2. aχ2 tests